Drugs and biologicals for use in the hospital, which are ordinarily furnished by the
            hospital for the care and treatment of inpatients are covered. Three basic requirements
            must be met for a drug or biological furnished by a hospital to be included as a covered
            hospital service. (1) The drug or biological must represent a cost to the institution
            in rendering services to the beneficiary. (2) It must either be included, or approved
            for inclusion, in the U.S. Pharmacopoeia, the National Formulary, or the U.S. Homeopathic
            Pharmacopoeia; or, except for those unfavorably evaluated, in AMA Drug Evaluations
            (the successor publication to New Drugs) or Accepted Dental Therapeutics (the successor
            publication to Accepted Dental Remedies); or be approved by the pharmacy and drug
            therapeutics or equivalent committee of the medical staff of the hospital for use
            in the hospital. (3) The drug or biological must be reasonable and necessary as specified
            in HI 00620.010.
         
         An investigational drug ordinarily is not considered as reasonable and necessary since
            its efficacy has not been established. Therefore, even if a drug or biological is
            approved by an appropriate hospital committee, the reasonable cost of an investigational
            or other non-approved drug or biological (e.g., Laetrile) cannot be reimbursed. This
            exclusion applies whether or not the drug or biological is administered during an
            otherwise covered hospital stay. (An exception has been made, however, for certain
            cancer drugs known as group C drugs, approved and distributed by the National Cancer
            Institute, in cooperation with the Food and Drug Administration for treatment by physicians
            who agree to participate in approved studies.)